How did Genprex's cost-cutting measures impact Q4 2024 profitability?

Genprex's cost-cutting measures had a significant impact on the company's Q4 2024 profitability, as evidenced by the following: 1. **Reduced Operating Expenses**: Genprex implemented expense reduction strategies, which led to a decrease in operating expenses. This reduction was achieved through cost-cutting measures such as reduced travel expenses, fewer professional service providers, and a decrease in headcount from 28 employees in 2023 to 16 employees in 2024. 2. **Decreased Research and Development Expense**: The company's research and development (R&D) expense decreased by $7.1 million, or 40%, due to changes in contract development and manufacturing organizations (CDMOs), lower manufacturing and R&D materials expenses, and a significant reduction in share-based compensation for R&D personnel. 3. **Lower General and Administrative Expense**: Genprex's general and administrative expense decreased by $2.8 million, or 21%, primarily due to expense reduction strategies that significantly lowered travel expenses, professional service provider costs, and headcount-related overhead. 4. **Impact on Net Loss**: As a result of these cost-cutting measures, Genprex's net loss for Q4 2024 was $21.1 million, which was a decrease of $9.7 million, or 32%, from the previous year. This reduction in net loss indicates that the cost-cutting measures were effective in improving the company's profitability for the period. In conclusion, Genprex's cost-cutting measures had a positive impact on the company's Q4 2024 profitability by reducing operating expenses, decreasing R&D and general and administrative expenses, and ultimately leading to a lower net loss. These measures demonstrate the company's strategic approach to managing costs while advancing its innovative therapies through clinical development.